---
schema_version: "secwatch.filing_event.v1"
accession: "0001570562-22-000116"
form_type: "8-K"
ticker: "EOLS"
cik: "0001570562"
company_name: "Evolus, Inc."
filed_at: "2022-08-02T23:59:59+00:00"
generated_at: "2026-06-24T05:54:34.211228+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolus Q2 revenue $37.2M (+42% YoY); reaffirms FY upper-end guidance $143-150M

## Summary
- Q2 net revenue $37.2M, up 42% YoY; gross margin 55.4% (adj. 57.4%); operating loss $21.3M.
- Reaffirms FY2022 revenue guidance upper end of $143-150M, expects ~50% YoY growth.
- Cash $84.5M; expects funding to cash-flow breakeven; Q4 gross margin step-up to 68-71% after royalty end.
- European Nuceiva launch on track for Q3 2022; Phase II 'extra strength' Jeuveau enrollment completed.
- Added 590 new customer accounts in Q2; total >8,100 purchasing customers; reorder rate >70%.

## SEC filing metadata
- accession: 0001570562-22-000116
- form_type: 8-K
- ticker: EOLS
- cik: 0001570562
- company_name: Evolus, Inc.
- filed_at: 2022-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1570562/000157056222000116/0001570562-22-000116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1570562/000157056222000116/eols-20220802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001570562-22-000116
- JSON: https://secwatch.observer/filing/0001570562-22-000116.json
- Plain text: https://secwatch.observer/filing/0001570562-22-000116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.